BR9812433A - Kay- uma proteìna do sistema de imunização - Google Patents

Kay- uma proteìna do sistema de imunização

Info

Publication number
BR9812433A
BR9812433A BR9812433-1A BR9812433A BR9812433A BR 9812433 A BR9812433 A BR 9812433A BR 9812433 A BR9812433 A BR 9812433A BR 9812433 A BR9812433 A BR 9812433A
Authority
BR
Brazil
Prior art keywords
kay
protein
immunization system
immunization
tnf
Prior art date
Application number
BR9812433-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jurg Tschopp
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9812433A publication Critical patent/BR9812433A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR9812433-1A 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização BR9812433A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
BR9812433A true BR9812433A (pt) 2000-09-26

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812433-1A BR9812433A (pt) 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização

Country Status (17)

Country Link
EP (1) EP1012270A2 (de)
JP (1) JP2001515711A (de)
KR (1) KR20010023892A (de)
CN (1) CN1269832A (de)
AU (1) AU9315298A (de)
BR (1) BR9812433A (de)
CA (1) CA2303424A1 (de)
EA (1) EA200000311A1 (de)
EE (1) EE200000148A (de)
HU (1) HUP0004034A3 (de)
IL (1) IL134480A0 (de)
IS (1) IS5375A (de)
NO (1) NO20001240L (de)
PL (1) PL339740A1 (de)
SK (1) SK3532000A3 (de)
TR (1) TR200000654T2 (de)
WO (1) WO1999012964A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999026463A2 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
IL148089A0 (en) * 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1309718A4 (de) * 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokin-alpha und spleiss-varianten von neutrokin-alpha
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EE05294B1 (et) 2001-05-11 2010-04-15 Amgen Inc. TALL-1-ga seostuv ainekompositsioon
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
RU2006117324A (ru) 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
EP2332563A3 (de) 2004-10-13 2013-03-13 The Washington University Verwendung von BAFF zur Behandlung von Sepsis
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3129380B1 (de) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Spiro[3h-indol-3,2'-pyrrolidin]-2(1h)-on-derivate und deren verwendung als mdm2-p53-hemmer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
ATE302272T1 (de) * 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
KR20010023892A (ko) 2001-03-26
NO20001240D0 (no) 2000-03-09
IS5375A (is) 2000-02-11
JP2001515711A (ja) 2001-09-25
NO20001240L (no) 2000-05-10
AU9315298A (en) 1999-03-29
EA200000311A1 (ru) 2000-10-30
WO1999012964A3 (en) 1999-05-27
SK3532000A3 (en) 2001-12-03
IL134480A0 (en) 2001-04-30
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
TR200000654T2 (tr) 2000-07-21
HUP0004034A2 (en) 2001-03-28
CA2303424A1 (en) 1999-03-18
EE200000148A (et) 2001-02-15
CN1269832A (zh) 2000-10-11
WO1999012964A2 (en) 1999-03-18
EP1012270A2 (de) 2000-06-28

Similar Documents

Publication Publication Date Title
BR9812433A (pt) Kay- uma proteìna do sistema de imunização
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
EA200000310A1 (ru) April - новый белок, воздействующий на рост
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
HUP0301789A2 (hu) Rekombináns anti CD40 ellenanyagok és használatuk
DK0833649T4 (da) Proteinhydrolysatpræparater til forebyggelse eller behandling af allergier
BR0014465B1 (pt) 1,1'-bifenil-2-carbonamidas 2'-substituÍdas, preparado farmacÊutico e aplicaÇÕes dos referidos compostos.
DE69000641D1 (de) Imipramin enthaltende arzneizubereitungen.
WO2004019872A3 (en) Oral delivery of modified transferrin fusion proteins
BR9606674B1 (pt) novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo.
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
BR9808625A (pt) O uso de proteìnas extraìveis de órgãos de animal para a preparação de medicamentos para o tratamento de condições patológicas caracterizadas por hiperprodução de fator de necrose de tumor (tnf)
PT952982E (pt) Novos inibidores da hepatite b
BR9714189A (pt) N-(piridinilamino) isoindolinas e compostos relacionados
BG104452A (en) New derivatives of the methylenebisphosphonic acid
ES2089091T3 (es) Complejos que contienen acidos s(+)-fenilalcanoicos y acidos alfa-hidroalcanoicos.
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
BR1101039A (pt) Composição farmacêutica para doenças renais ou cardiovasculares

Legal Events

Date Code Title Description
PC Transfer

Free format text: APOTECH R&D S.A. (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.